Tolebrutinib Long-term Data Continue to Show the BTK Inhibitor Is Safe, Clinically Effective in MS

Tolebrutinib is an Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

Related Keywords

Boston ,Massachusetts ,United States ,Toronto ,Ontario ,Canada ,American ,Wexlerm Tolebrutinib , ,University Of Toronto ,American Academy Of Neurology ,Barlo Multiple Sclerosis Program ,American Academy ,Expanded Disability Status Scale ,Term Safety ,Efficacy Study ,Participants With Relapsing Multiple ,Relapsing Multiple ,Updated May ,Sar442168 ,Tolebrutinib ,Btk Inhibitor ,